A Multi-centre, Double-blind, Randomised Trial Investigating the Efficacy and Safety of a Combination Therapy, Desmopressin and Tolterodine, for Treatment of Overactive Bladder With Nocturia in Women
Latest Information Update: 22 Aug 2018
At a glance
- Drugs Desmopressin (Primary) ; Tolterodine (Primary)
- Indications Nocturia; Overactive bladder
- Focus Proof of concept; Therapeutic Use
- Sponsors Ferring Pharmaceuticals
- 09 Oct 2015 Results of post-hoc analysis presented at the 45th Annual Meeting of the International Continence Society
- 09 Oct 2015 Results presented at the 45th Annual Meeting of the International Continence Society
- 03 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.